BSX Stock Price Today (October 2026) — Boston Scientific Corporation Analysis & Key Metrics 2026-10-21
Boston Scientific Corporation (BSX) is trading at $45.58, up 1.18% today (as of October 2026). The stock continues to show early recovery signs above the short-term average, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $59.24 (30.0% upside).
- Volatility is low (20.95% annualized), implying relatively contained price movements for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (7.50% YoY) alongside competitive pressures in the Medical Devices space.
BSX Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Boston Scientific Corporation - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $78.14B
P/E Ratio
Forward P/E: 14.07
Revenue Growth
Year over Year
Analyst Target
+30.0% upside potential
Key Investor Questions About BSX
What investors need to know before buying
Based on current market data, BSX presents a neutral technical setup with looking solid fundamentals.
- Technicals say: Neutral (RSI 54.74)
- Fundamentals say: Looking solid (debt and growth supportive)
BSX's growth trajectory depends on its ability to expand within the Medical Devices sector while managing margin pressures.
- Future growth will depend on performance in core Medical Devices operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for BSX investors include debt exposure and competitive dynamics in the Medical Devices industry.
- $12.62B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Medical Devices.
52-Week Trading Range
Over the past year, BSX stock traded between $41.39 and $105.65 and currently trades near the low end of that range. Big swings are less likely unless a major catalyst emerges.
Volatility & Risk Profile
With 20.95% annualized volatility and β=0.23, the stock exhibits low sensitivity to market moves—making BSX suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional ownership with low short interest suggests steadier hands and low immediate risk.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines, coverage and TickZen analysis
Market news
Vertex Appoints Daniel Brennan to its Board of Directors
Is Medtronic Stock A Buy Now That Sales Growth Has Picked Up?
Boston Scientific (BSX) Rises Higher Than Market: Key Facts
Is Boston Scientific Stock Riskier Than It Was A Year Ago?
Baird Adjusts Price Target on Boston Scientific to $50 From $53
Latest TickZen Insights
All insights →No TickZen article on BSX yet. Our newest analysis:
Explore More Analysis for BSX
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Oct 28, 2026 (before the open)
Frequently Asked Questions
Common investor questions about Boston Scientific Corporation
Boston Scientific Corporation (BSX) is currently trading at $45.58. The RSI (14-day) is at 54.7, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $59.24 implies 30.0% upside from current levels. Volatility is moderate at 21.0% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Boston Scientific Corporation (BSX): The trailing P/E ratio is 18.24, which is in line with broader market averages. The forward P/E is 14.07, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 0.67, below 1.0, which generally indicates the stock is undervalued relative to its growth rate. Price-to-Book is 2.61. Price-to-Sales is 3.11. Valuation should be compared to Medical Devices industry peers for context, as different sectors trade at different multiples.
Based on 29 analysts covering BSX, the consensus price target is $59.24. This represents a 30.0% upside from the current price of $45.58. The range spans from a low target of $44.00 to a high target of $94.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Boston Scientific Corporation (BSX) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Boston Scientific Corporation (BSX) investors include: 1. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 2. Medical Devices sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Boston Scientific Corporation's (BSX) current debt and financial health profile: Total debt stands at $12.62B. The debt-to-equity ratio is 0.50x, which is moderate and generally manageable for most companies. The current ratio is 1.24, indicating adequate short-term liquidity. The quick ratio is 0.56. The company holds $539.00M in cash and equivalents. Free cash flow is positive at $2.45B, providing a cushion for debt servicing and shareholder returns.